These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22959552)

  • 1. Advances in the management of venous thromboembolism.
    Schulman S
    Best Pract Res Clin Haematol; 2012 Sep; 25(3):361-77. PubMed ID: 22959552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The promise of novel direct oral anticoagulants.
    Hoffman R; Brenner B
    Best Pract Res Clin Haematol; 2012 Sep; 25(3):351-60. PubMed ID: 22959551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New oral anticoagulants: should they replace heparins and warfarin?
    Tsiara S; Pappas K; Boutsis D; Laffan M
    Hellenic J Cardiol; 2011; 52(1):52-67. PubMed ID: 21292607
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism management: where do novel anticoagulants fit?
    Spyropoulos AC; Turpie AG
    Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Old versus new anticoagulants: focus on pharmacology.
    Benmira S; Banda ZK; Bhattacharya V
    Recent Pat Cardiovasc Drug Discov; 2010 Jun; 5(2):120-37. PubMed ID: 20337579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current status of the management of venous thromboembolism in Japan].
    Nakamura M
    Nihon Rinsho; 2014 Jul; 72(7):1298-302. PubMed ID: 25163325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].
    Pernod G; Elias A; Gouin I; Gaillard C; Nguyen P; Ouvry P; Sié P
    J Mal Vasc; 2012 Dec; 37(6):300-10. PubMed ID: 23122646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rivaroxaban: mode of action].
    Drouet L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
    Arepally GM; Ortel TL
    Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
    Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
    Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New anticoagulants in the prevention and treatment of venous thromboembolism].
    Keltai M; Keltai K
    Orv Hetil; 2011 Jun; 152(25):983-92. PubMed ID: 21642050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
    Prandoni P; Barbar S; Milan M; Vedovetto V; Pesavento R
    Eur J Intern Med; 2014 Jan; 25(1):25-30. PubMed ID: 24120221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
    Galanis T; Merli GJ
    Hosp Pract (1995); 2013 Feb; 41(1):26-36. PubMed ID: 23466965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
    Quinlan DJ; Eriksson BI
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Morell J; Sullivan B; Khalabuda M; McBride BF
    J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging anticoagulants for the treatment of venous thromboembolism.
    Weitz JI
    Thromb Haemost; 2006 Sep; 96(3):274-84. PubMed ID: 16953267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.